Patients in Intensive Care Units (ICUs) often suffer from delirium, including experiencing disorientation and witnessing hallucinations. Going through delirium has shown to negatively affect patient outcomes, in addition to being a hindrance to receiving proper medical care while hospitalised. For these reasons acute delirium should be dealt with, but there are few real treatment options. Philips is now releasing a solution to help reducing the incidence and severity of delirium in hospitalized patients. As part of that solution Philips has developed an innovative light therapy system which recently received CE Mark and is now commercially available in Germany, Austria, Switzerland, Finland and Sweden, with market launches planned in other countries over the next years.

RENOLIT has been selected by Philips Health Systems - after a thorough procedure of testing of many different qualities - as the Best Supplier of the translucent Diffusing film for the light therapy device. Excellent stability in Quality Supply and premium certification of the RENOLIT Translucent Stretch Ceiling films have been the key drivers for Philips Health Systems to choose for RENOLIT as preferred supplier.